Bendamustine, Prednisone and Velcade for First-line Treatment of Patients With Symptomatic Multiple Myeloma Not Eligible for High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation (BPV).
Phase of Trial: Phase II
Latest Information Update: 03 Dec 2018
Price : $35 *
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Prednisone (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 30 Nov 2018 Status changed from active, no longer recruiting to completed.
- 12 May 2018 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2018.
- 15 May 2017 Planned End Date changed from 1 Mar 2019 to 1 Oct 2018.